19

New pharmaceuticals resulting from complex innovative processes have unsettled the -emics and -etics categorizations of medicines. Between biomedicine and Chinese medicine knowledge production processes, they are part of an “integrated” medicine promoted within the framework of the Chinese public health system while circulating in networks operating at local, national, or international levels. Based on two case studies, the ACT (Artemisinin-combination therapies) currently recommended by WHO for malaria treatment, and the Tang herbal tablet ( Tang caopian) used in China for complementary HIV treatment, the article is organized into two main parts. The first part documents research and development of new pharmaceuticals and raises issues relative to these processes. The second part discusses the definition of a new product from several -etics views and their nature of “hybrid objects” through the identification of extended networks,” concepts borrowed from Latour (1991).